Nachrichten zur Esperion Therapeutic.Inc. Aktie

Esperion to Report Third Quarter 2020 Financial Results November 2, 2020

ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third…

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol

ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break…

Esperion to Participate in Two Upcoming Virtual Investor Conferences

ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion…

Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020

ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 19,…

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales....…

Esperion Therapeutics Inc (ESPR) Q2 2020 Earnings Call Transcript

ESPR earnings call for the period ending June 30, 2020....…

Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do…

Esperion Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics, Inc.: 10-Q Report

FORM 10-Q...…

Esperion Therapeutics, Inc.: 8-K Report

FORM 8-K...…

Esperion Therapeutics Q2 2020 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion to Report Second Quarter 2020 Financial Results August 10, 2020

ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second…

Esperion Therapeutics: An Easy Double, Maybe A Lot More

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics, Inc.: 8-K Report

FORM 8-K...…

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

ANN ARBOR, Mich., June 22, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced the completion of an amendment…

The Play On Esperion Therapeutics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from…

Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER

ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice…

Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference

ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief…

All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by…

Esperion Therapeutics (ESPR) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion: Early Commercial Success Supports A Buy At These Prices

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15,…

Esperion Has A Low Bar To Climb To Warrant Its Present Valuation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics Inc (ESPR) Q1 2020 Earnings Call Transcript

ESPR earnings call for the period ending March 31, 2020....…

Esperion Therapeutics (ESPR) CEO Tim Mayleben on Q1 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Therapeutics EPS beats by $0.49, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion to Report First Quarter 2020 Financial Results May 6, 2020

ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first…

Esperion out-licenses bempedoic acid meds in Japan to Otsuka

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets in Japan

- Esperion to Receive $60 Million Upfront Payment -...…

Esperions Cholesterol Drugs Receive Approval in Europe

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe....…

Esperions Nustendi OKd in Europe

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces European Commission Approval of the NUSTENDI (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

- First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe -...…

Esperion Announces European Commission Approval of the NILEMDO (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients -...…

Esperion launches cholesterol med bempedoic acid in U.S.

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Esperion Announces Commercial Availability of the NEXLETOL (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a…

Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound-

Esperion Therapeutics (ESPR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Esperion Announces Three Data Presentations of the NEXLETOL (bempedoic acid) Tablet and the NEXLIZET (bempedoic acid and ezetimibe) Tablet at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Ca

ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from…

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Card

ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from…

The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperions Lipid-Lowering Adjunctive Combo Therapy

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks…